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Abstract
As with other solid tumors, the growth and metastasis of pancreatic cancer is critically dependent
on tumor angiogenesis. A major stimulus for a tumor's recruitment of additional blood vessels is
cellular hypoxia, a condition which is especially pronounced in this neoplasm. Hypoxia induces
transcriptional activation of genes that alter cellular metabolism and promote neoangiogenesis.
Pancreatic cancer cells have demonstrated activation of such adaptive pathways even in the absence
of hypoxia. A highly-angiogenic response in this neoplasm correlates with increased tumor growth,
increased metastasis, and decreased survival. Pancreatic cancers expressing high levels of vascular
endothelial growth factor, a potent pro-angiogenic cytokine, also have a higher incidence of
metastasis and poorer prognosis. Pancreatic cancer cells uniquely express receptors for vascular
endothelial growth factor, indicating a role for an autocrine loop in tumor proliferation and
invasion. Multiple experimental anti-angiogenic strategies, many of which target vascular endothelial
growth factor, reduce pancreatic cancer growth, spread, and angiogenesis. Anti-angiogenic
treatments for pancreatic cancer will likely be most effective when used as an integral part of a
combination chemotherapeutic regimen.
Introduction
Adenocarcinoma of the pancreas remains a most formida-
ble malignancy. Usually undiagnosed until reaching an
advanced stage, pancreatic cancer is characterized by its
predisposition to aggressively invade surrounding tissues,
to metastasize early and extensively, and to resist conven-
tional chemoradiation treatment strategies. Recent esti-
mates project that over 30,000 new cases of pancreatic
cancer will be diagnosed in the United States in 2002, and
the annual mortality rate closely approaches that of the
number of new cases [1]. Despite diagnostic and thera-
peutic advances made in other gastrointestinal malignan-
cies, the overall five-year survival for patients with
pancreatic cancer remains a dismal 3 to 4% [1]. Improve-
ment in the treatment of this disease must arise from a
better understanding of the cellular and molecular mech-
anisms utilized by the cancer to proliferate, invade sur-
rounding tissues, and elude cytotoxic therapies. As with
other solid tumors, there has been a surge in the study of
pancreatic tumor neovascularization that is critical to
growth and metastasis.
The notion that a growing mass of tumor cells must recruit
its own blood supply for the maintenance of oxygen and
nutrients, termed tumor angiogenesis, was popularized by
Judah Folkman in the early 1970s [2]. Since this first de-
scription of angiogenesis as a requisite process for contin-
uous solid tumor growth, many endogenous pro- and
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resident and stromal cells, and infiltrating lymphocytes
have been characterized [3–7]. As a solid tumor grows,
some cells inevitably become physically separated from
the native tissue's nutrient vascular stroma, and delivery
of nutrients and oxygen to those cells becomes limited by
diffusion [1,8]. The end result is metabolic stress and cel-
lular hypoxia – conditions thought to be major stimuli
underlying the recruitment of additional blood vessels
[9]. Hypoxia induces changes in transcriptional regulation
that serve to alter cellular metabolism (i.e., shift to glyco-
lytic pathways) and promote the ingrowth of immature,
architecturally deranged, and highly permeable blood ves-
sels that facilitate the passage of tumor cells into the circu-
lation [9–12]. Thus, a cancer's response to hypoxia not
only sustains tumor growth and survival, but through an-
giogenesis it fosters invasion and metastasis. Indeed, hy-
poxic tumors have been reported to have a predilection
for tissue invasion and metastasis [13,14]. Such adaptabil-
ity has been proposed to be especially relevant in pancre-
atic cancer, a malignancy that exhibits a profound and
characteristic avascular, hypodense appearance on con-
trast-enhanced computerized tomography of the abdo-
men [15].
In this article we will review the relevant data characteriz-
ing pancreatic cancer as an hypoxic tumor, and discuss the
molecular mechanisms by which this neoplasm responds
to hypoxia, generates new blood vessel growth, and pro-
motes its own growth and metastasis.
Hypoxia in cancer tumorigenesis and metastasis
Discussion of the role of hypoxia in pancreatic cancer re-
quires some background on the effects of hypoxia on can-
cer cells in general. A role for an hypoxic
microenvironment in the pathogenesis and progression
of human cancer was first proposed in 1953, when well-
oxygenated tumor cells were found to exhibit 3-fold great-
er response to radiotherapy when compared to anoxic
cells [16]. The reasons why tumors become hypoxic re-
main unclear, but multiple mechanisms likely contribute
to its development. These include unrestrained growth
and accelerated oxygen consumption by tumor cells; poor
lymphatic drainage of tumors resulting in high interstitial
pressures, vascular collapse, and low pH; and intratumor-
al shunting of oxygen-rich blood through immature vas-
culature [10]. Furthermore, tumor angiogenesis may not
necessarily equate to tumor blood supply, as the discon-
tinuous basement membrane of immature neo-angiogen-
ic vessels allows for the extravasation of plasma and
proteins, further increases in intratumoral interstitial pres-
sure, continued vascular collapse, and poor nutrient deliv-
ery [10]. Some tumors also demonstrate an inability to
preserve blood vessel survival, a condition which accounts
for the well-vascularized, invasive periphery and the hy-
poxic area of central necrosis found in several highly ang-
iogenic tumors [17].
Experimental evidence suggests that tumor cells exist un-
der hypoxic conditions at a distance of 300–400 µm from
blood vessels, indicating that hypoxic conditions are gen-
erally established in tumors measuring only 0.5 mm in
diameter [18]. In order to increase oxygen availability (an-
giogenesis) or to decrease oxygen consumption (i.e., shift
to glycolytic metabolism), tumor cells alter their transcrip-
tion of a wide range of genes whose protein products serve
to stimulate blood vessel growth (pro-angiogenic factors)
or to modulate cellular glucose metabolism (glycolytic en-
zymes) [10]. A large number of genes are now known to
be regulated by hypoxia, including those encoding eryth-
ropoietin, vascular endothelial growth factor (VEGF), gly-
colytic enzymes, and inducible nitric oxide synthase
(iNOS) [19–22].
Hypoxia-inducible genes contain hypoxia response ele-
ments (HREs) – sequences of around 50 base pairs that
bind hypoxia-activated transcription factors [23–25]. Sev-
eral of these transcription factors have been described,
and the most important and best understood is the Hy-
poxia Inducible Factor-1 (HIF-1) [24–29]. HIF-1 was orig-
inally identified in 1992 in Hep3B cells as a nuclear
protein factor induced by hypoxia with binding activity to
an enhancer in the erythropoietin gene [26]. HIF-1 is a
heterodimer formed by the association of α – and β-sub-
units (HIF-1α and HIF-1β), both of which belong to the
basic helix-loop-helix (bHLH) – PAS (PER, ARNT, SIM)
family of transcription activator proteins (see Figure 1)
[29,30]. HIF-1β is also known as the aryl hydrocarbon re-
ceptor nuclear translocator (ARNT) [30–32]. While HIF-
1β protein is constitutively expressed in mammalian cells
under normoxic conditions, virtually no HIF-1α is found
[24]. Under normoxic conditions, the cellular half-life of
HIF-1α is around 5 minutes, as the protein is rapidly de-
graded by the ubiquitin-proteasome system [24,33,34].
Under hypoxic conditions, the HIF-1α protein is stabi-
lized by the absence of posttranslational hydroxylation
events at PRO 564 of the HIF-1α molecule [24].
Stable HIF-1α translocates to the nucleus in a process me-
diated by specific nuclear localization signals and dimer-
izes with HIF-1β [24]. To activate transcription of
hypoxia-regulated genes, the intact heterodimeric HIF-1
complex binds DNA at specific HREs characterized by the
consensus sequence 5'-RCGTG-3' [23]. Within the HIF-1
complex, the HLH and PAS-domains mediate factor
dimerization, whereas the basic domain binds directly to
DNA HREs [24]. Once nuclear translocation and dimeri-
zation are complete, activation of transcription occurs
through interactions between co-activator proteins and
two transactivation domains (TADs), both of which arePage 2 of 10
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[23]. In summary, hypoxic conditions lead to HIF-1α sta-
bilization and translocation to the cell nucleus, dimeriza-
tion with HIF-1β to form the HIF-1 complex, and
activation of transcription through HIF-1's binding to spe-
cific HREs in target sequences (see Figure 2).
While hypoxia is the major stimulus for HIF-1α stabiliza-
tion and activation, some evidence indicates that cellular
constituents participate in the regulation of HIF-1α activ-
ity as well. The von Hippel-Lindau protein (pVHL) is the
product of the VHL gene, a tumor-suppressor gene known
to be inactivated in renal clear-cell carcinomas as well as
other markedly vascular tumors such as central nervous
system hemangioblastoma [24]. The VHL protein con-
tains a binding site in the oxygen-dependent degradation
domain (ODD) of HIF-1α between amino acids 401–603
[35–37]. As the VHL protein is a subunit in the multimeric
E3 ubiquitin ligase complex, its binding to the ODD re-
gions of HIF-1α leads to ubiquitin conjugation and degra-
dation of the factors by the ubiquitin proteasome system.
Thus, loss of the VHL protein results in constitutive stabi-
lization of HIF-1α and transactivation of genes promoting
vasculogenesis (i.e., VEGF) [24,35–37]. In addition, phos-
phorylation of HIF-1α by the p44/42 mitogen activated
protein kinases (MAPK) results in enhanced transcription-
al activation independent of cellular hypoxia [38]. Exper-
imental evidence suggests that p44/42 MAPK
phosphorylation events are required for transcriptional
activation mediated by HIF-2α, a related hypoxia-induced
factor also known as endothelial PAS-protein-1 (EPAS-1)
[39].
Compared to normal tissue controls, HIF-1 protein has
been shown through immunohistochemical studies to be
overexpressed in several human cancers, including colon,
breast, gastric, lung, skin, ovarian, prostate, renal, and
pancreatic carcinomas [40]. Interestingly, in these studies,
HIF-1α positive cells were noted to be crowded most
densely at a tumor's infiltrating margin, around the pe-
riphery of necrotic areas, and surrounding regions of high
microvessel density [40]. HIF-1α expression was also
more pronounced in nodal and bone metastases than in
primary tumor specimens [40]. Premalignant lesions such
as breast comedo-type ductal carcinoma in situ, prostatic
intraepithelial neoplasia, and colonic adenoma showed
HIF-1α positivity, whereas benign lesions (mammary fi-
broadenoma and uterine leiomyoma) did not [40]. These
results emphasize that HIF-1α plays an important role in
cancer growth and metastasis. Its overexpression may rep-
resent an early event in carcinogenesis and may eventually
serve as a possible biomarker for precancerous disease.
Hypoxia in pancreatic cancer pathogenesis and 
progression
The presence of significant hypoxia in pancreatic cancers
has been long suspected, especially given these lesions'
characteristic avascular appearance on contrast-enhanced
CT scan [15]. Hypoxia in pancreatic cancer was first docu-
mented by Koong and colleagues in 2000, when they re-
ported results from direct intratumoral needle O2
measurements at the time of resection in seven patients
with operable pancreatic cancers [41]. Areas of pancreatic
carcinoma exhibited median pO2 levels of 0–5.3 mmHg
with 24–94% of samplings having pO2 levels less than 2.5
mmHg [41]. In contrast, adjacent areas of normal pancre-
atic tissue had median tissue pO2 levels of 24–92.7 mm-
Hg, and no more than 9% of any samplings had
measurements less than 2.5 mmHg (seven patients had
no levels < 2.5 mmHg) [41]. In our own unpublished ex-
perience we have found similar levels of hypoxia meas-
ured by intraoperative needle measurement. Earlier we
demonstrated profound pancreatic tissue hypoxia in
chronic pancreatitis, a condition that usually co-exists in
pancreatic cancer patients [42].
Our laboratory has confirmed that HIF-1 is activated in
pancreatic cancer in response to low oxygen levels in vitro
and in vivo [43]. Studies in human specimens of pancreat-
ic cancer showed co-localization of VEGF mRNA, which is
produced in ductal cancer cells, and HIF-1α protein,
which was detectable in the cell nuclei of cancer cells [43].
HIF-1α mRNA expression was dramatically upregulated
in human pancreatic cancer specimens [43]. In vitro all
Figure 1
Structure of the HIF-1 Complex. The hypoxia inducible fac-
tor 1 complex (HIF-1) is a dimer composed of two proteins 
involved in hypoxic gene transactivation, HIF-1α and HIF-1β 
(ARNT). Dimerization between these two factors is medi-
ated by the helix-loop-helix (HLH) and Per-ARNT-SIM 
domains, and DNA binding involves the basic (b-) region of 
the b-HLH domains. HIF-1 modulates transcription through 
its transactivation domains (TAD). Between amino acids 401 
and 603, HIF-1α contains an oxygen-dependent degradation 
domain (ODD) which controls its degradation under nor-
moxia [24]. Fig. 1
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under low oxygen levels by highly specific activation of
HIF-1 DNA binding activity to the VEGF promotor [43].
Cell lines with high constitutive levels of HIF-1α protein
were found to produce higher basal levels of VEGF [43].
Thus it appears that HIF-1 is the link between tumor hy-
poxia and VEGF production in pancreatic cancer.
The effects of an hypoxic environment on pancreatic can-
cer cells are beginning to be understood on a molecular
level. Our laboratory has recently collaborated in the
identification of three genes induced by hypoxia in vitro in
the well-differentiated human pancreatic cancer cell line
Capan-2 [44]. The genes are GPI/NLK/AMF (glucose
phosphate isomerase/neuroleukin/autocrine motility fac-
tor), DEC1, and hexokinase II [44]. These results marked
the first evidence that DEC1 and hexokinase II were hy-
poxia-induced in human pancreatic cancer and represent-
ed the initial report of hypoxic-regulation of GPI/NLK/
AMF in any human system [44]. Additional studies are
Figure 2
Molecular mechanisms of hypoxia-induced angiogenesis. Under normoxic conditions (panel A), HIF-1α is hydroxylated by the 
active prolyl-4-hydroxylase enzyme, which facilitates the binding of VHL protein and leads to rapid HIF-1α degradation by the 
ubiquitin proteasome system. In the face of hypoxia (panel B), the hydroxylase enzyme is inactive and HIF-1α is stabilized in its 
de-hydroxylated state. The stable HIF-1α translocates to the nucleus, where it accumulates and dimerizes with the constitu-
tively expressed HIF-1β, forming the intact HIF-1 complex. This complex binds hypoxia response elements (HREs) in selective 
genes to alter transcriptional activity. A notable hypoxia-induced gene is that coding for vascular endothelial growth factor 
(VEGF), a cytokine which potently stimulates neoangiogenesis [24].Page 4 of 10
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the development and progression of pancreatic cancer.
Interestingly, recent studies are beginning to define a role
for HIF-1α in pancreatic cancer independent of an hypoxic
environment. Akakura et al have reported expression of
HIF-1α protein in several human pancreatic cancer cell
lines in normoxic conditions [45]. This constitutive HIF-
1α expression improved pancreatic cancer cell prolifera-
tion and survival under hypoxic and glucose-deprived
conditions in vitro, results that were associated with in-
creased mRNA expression of Glut1 and aldolase A, both
glycolytic enzymes [45]. These studies demonstrate that
pancreatic cancer cells can survive and proliferate despite
hypoxia and glucose deprivation, and HIF-1α likely medi-
ates their adaptive cellular responses [45]. However, they
also emphasize that in human pancreatic cancer cells,
HIF-1α stabilization and activity may be promoted
through primary intracellular alterations not induced by
hypoxia.
Recent evidence indicates that the hypoxic adaptive re-
sponse in pancreatic cancer cells may also involve upreg-
ulation of pro-inflammatory cytokines. Shi et al
demonstrated that pancreatic cancer cells which constitu-
tively expressed high levels of interleukin-8 (IL-8), a pro-
angiogenic ELR+ member of the -CXC- chemokine family,
formed larger tumors with more extensive metastases in
an orthotopic mouse model [46]. Immunohistochemical
analyses of tumors revealed that IL-8 upregulation was
clustered primarily near areas of tumor necrosis, sites like-
ly to have the most acidic interstitial pH and the lowest
levels of diffusible oxygen and nutrients [46]. In vitro ex-
posure to hypoxia increased expression of IL-8 in all cell
lines examined [46]. Treatment with IL-8 antisense oligo-
nucleotides resulted in decreased tumor growth and ang-
iogenesis in vivo [46]. Unpublished results from our
laboratory have demonstrated constitutive secretion of
additional pro-angiogenic CXC chemokines by multiple
cell lines of human pancreatic cancer. Further studies will
continue to unravel the mechanisms by which pro-and
anti-angiogenic inflammatory cytokines modulate angio-
genesis and growth of pancreatic adenocarcinoma.
Neoangiogenesis in pancreatic cancer
Interest in tumor angiogenesis in pancreatic cancer stems
not only from this tumor's remarkable tendency toward
early local tissue invasion and metastasis, but also from its
characteristic hypodense, hypovascular appearance on
contrast-enhanced computerized tomographic scans.
While investigation into angiogenesis in pancreatic cancer
may appear contradictory at first, it is important to keep
in perspective that CT-enhancement reflects intra-and per-
itumoral macro-vessels, not micro-vessels. Furthermore,
several lines of evidence indicate that neoangiogenesis is
an important component in pancreatic cancer growth and
metastasis [47,48].
Pancreatic adenocarcinomas exhibit high levels of intratu-
moral microvessel density
Several studies have evaluated pancreatic adenocarcino-
mas for intratumoral microvessel density (IMD) profiles
suggestive of significant tumor-induced angiogenesis.
Through immunohistochemistry, Kuehn et al found IMD
to be increased in pancreatic cancer specimens over that of
normal pancreas and chronic pancreatitis specimens [49].
Other researchers have found high IMD in pancreatic can-
cer to correlate with poor patient survival [50–54]. In an
immunohistochemical analysis of 22 pancreatic
adenocarcinoma specimens, Karademir and colleagues
found that a tumor's vascular surface density and number
of microvessels per mm2 of stroma correlated with in-
creased tumor proliferation, poor differentiation, larger
tumor size (>3 cm), and decreased patient survival [54].
Further support has come from Fujioka et al who found
that high IMD in pancreatic tumors correlated with signif-
icantly reduced overall and disease free survival rates [55].
In addition, those tumors with high IMD had significant-
ly-increased incidence of hepatic metastasis compared to
low-IMD tumors [55]. Conversely, an immunohisto-
chemical study by Ellis and colleagues of 22 pancreatic ad-
enocarcinoma specimens demonstrated no significant
correlation between IMD/VEGF expression and patient
survival or time to recurrence [56]. Despite these findings,
the vast majority of data at this point indicate that pancre-
atic adenocarcinomas exhibit a high degree of angiogen-
esis; and, as has been demonstrated in other solid tumors
such as breast, lung, prostate, cervix, and colon cancer,
high IMD correlates with poorer prognosis and greater
risk for metastasis [50–55,57–61].
Angiogenic factors and their receptors are expressed by 
pancreatic adenocarcinomas
The process of angiogenesis reflects a balance between
pro- and anti-angiogenic factors in the peri-tumoral mi-
lieu [12]. Although several pro- and anti-angiogenic fac-
tors are expressed by pancreatic adenocarcinomas [62–
65], much of the research in pancreatic cancer thus far has
centered on vascular endothelial growth factor (VEGF).
First described in 1979 as a tumor-secreted protein that
profoundly increased microvascular permeability in sub-
cutaneous tumors in guinea pigs (originally termed vascu-
lar permeability factor) [66], VEGF subsequently has been
noted to stimulate endothelial cell proliferation and mi-
gration, to influence endothelial cell gene activation, and
to act on endothelial cells as an anti-apoptotic agent [67–
69]. It should be noted that VEGF's initial function, ren-
dering tumor microvessels markedly permeable to plasma
and proteins, is paramount to tumor growth and progres-
sion through angiogenesis: the resultant extravascularPage 5 of 10
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Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/12fibin-rich stroma provides a nutrient scaffold upon which
activated endothelial cells can migrate and form vascular
tubes [70].
VEGF represents the original dimeric cytokine belonging
to the platelet-derived growth factor (PDGF) family of
growth factors, with members including VEGF-A (vascular
permeability factor), VEGF-B, VEGF-C, VEGF-D, VEGF-E,
and placenta growth factor (PlGF) [70]. Investigation in
pancreatic cancer has focused thus far on VEGF-A, a di-
sulfide-bonded dimeric glycoprotein of 34–45 kDa en-
coded on chromosome 6p and existing as several isoforms
secondary to differential splicing (VEGF-A165 is the most
commonly found isoform) [70]. VEGF-A exerts its effects
on target endothelial cells through interactions with its
two specific transmembrane tyrosine kinase receptors,
VEGFR-1 (Flt-1) and VEGFR-2 (KDR, flk-1) [70]. These re-
ceptors are selectively expressed on endothelial cells, but
rarely they may also be expressed on some tumor cells.
Upon binding VEGF-A, the VEGF receptors dimerize, un-
dergo autophosphorylation, and propagate signals
through multiple intracellular pathways, including the
MAPK, PI3-kinase, Ras, and phospholipase C cascades
[70]. VEGFR-2 appears to modulate endothelial cell pro-
liferation and migration, and increases microvessel per-
meability, whereas the actions of VEGFR-1 are not yet
fully described [70]. Mice null (-/-) for either VEGFR have
abnormal vasculogenesis and die during embryogenesis
[70].
Recently, the neuropilins 1 and 2, known to be receptors
for axonal guidance factors of the semaphorin family,
have been identified as additional receptors for some
VEGF-A isoforms [71–73]. Existing evidence indicates that
neuropilin-1 acts as a coreceptor which enhances the ac-
tivity of VEGFR-2 upon binding to VEGF-A165, leading to
increased endothelial cell migration [73]. Neuropilin-2 is
also able to bind VEGF-A165, but unlike neuropilin-1, it
also interacts with VEGF-A145 [70,72,73]. The roles of the
non-kinase neuropilins in tumor-induced angiogenesis
are now beginning to be examined [70].
Several studies have examined VEGF-A expression and
function in pancreatic cancer. The first evidence for VEGF-
A expression was immunopositive staining of a single
pancreatic cancer specimen [74]. Multiple subsequent
studies have confirmed VEGF expression by pancreatic
cancer and have demonstrated correlation between high
tumoral expression and poor prognosis [75–80]. VEGF-A
overexpression has been detected in the ascites induced by
pancreatic cancer metastases [81]. Seo et al demonstrated
VEGF-A protein in 132/142 (93%) human pancreatic can-
cer specimens using immunohistochemistry, and high
VEGF positivity correlated directly with increased IMD
and presence of hepatic metastasis [75]. Also, patients
with high VEGF tumor expression had significantly short-
er survival than did those with low to absent expression
[75]. However, in this study, VEGF expression by pancre-
atic cancers failed to correlate with tumor size, lymph
node metastasis, vascular invasion, perineural invasion,
peritoneal carcinomatous implants, or local recurrence
[75]. Itakura et al examined VEGF expression in both hu-
man pancreatic cancer cell lines and histologic specimens
[76]. They demonstrated VEGF mRNA and protein expres-
sion in all cultured cell lines and specimens examined,
and they noted that pancreatic cancer tissue had a greater
than 5-fold increase in VEGF mRNA versus normal pan-
creatic control tissue [76].
Furthermore, immunohistochemical analysis of 75 pan-
creatic cancer tissues showed specific VEGF positivity in
the cancerous cells in 64% of all tissues examined [76].
High VEGF expression in pancreatic cancer tissue on im-
munohistochemistry directly correlated with increased
IMD, larger tumor size, and enhanced local spread, but
not with decreased patient survival [76]. Additional stud-
ies by this group have confirmed overexpression of VEGF
mRNA and protein compared to normal pancreas, and in-
terestingly, have demonstrated the presence of VEGF re-
ceptors, VEGFR-1 and VEGFR-2, on both cultured human
pancreatic cancer cells (AsPC-1, Capan-1, and MIA PaCa-
2) and tissue specimens [82]. Functional receptor binding
studies by this group confirmed high levels of VEGF-VEG-
FR interaction only in Capan-1 cells; VEGF dose-depend-
ently enhanced proliferation, promoted MAPK
phosphorylation, and induced c-fos activity only in these
Capan-1 cells [82]. These results were later reinforced by
von Marschall et al, who demonstrated overexpression of
VEGF and VEGF receptors in cancerous ductal epithelial
cells versus normal pancreas and chronic pancreatitis
specimens using immunohistochemistry and in-situ hy-
bridization [83]. VEGF and VEGFR were also demonstrat-
ed in human pancreatic cancer cell lines, although, in
contrast to the Itakura et al study, no VEGFR mRNA was
detected in cultured Capan-1 cells (VEGFR-1 mRNA-posi-
tive cells were AsPC-1, Dan-G, and PANC-1; VEGFR-2
mRNA-positive cells were AsPC-1 and Dan-G) [83]. In
this study, multiple cell lines of human pancreatic cancer
actively secreted VEGF, and treatment of VEGFR-positive
cells with VEGF produced significant enhancement of
pancreatic cancer cell growth [83]. Therefore, in contrast
to other malignancies, in pancreatic cancer VEGF not only
influences endothelial cells and tumor angiogenesis, but
it appears to be a unique autocrine mitogen for the malig-
nant ductal epithelial cells themselves.
Our laboratory has continued the investigation into the
roles of VEGF and its receptors in pancreatic cancer. Our
results confirmed the presence of VEGF, VEGFR-1, andPage 6 of 10
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in multiple human pancreatic cancer cell lines [84]. Im-
munohistochemistry of human pancreatic cancer speci-
mens demonstrated positive VEGFR-1 and VEGFR-2
staining, and VEGFR-2 positivity correlated significantly
with shorter survival [84]. In vitro, VEGF stimulation sig-
nificantly increased pancreatic cancer cell proliferation, an
effect that was abrogated by treatment with antisense oli-
gonucleotides for VEGFR-2, but not for VEGFR-1 [84]. Fi-
nally, in an orthotopic nude mouse model of human
pancreatic cancer, VEGFR-2 antisense oligonucleotide
treatment significantly decreased tumor growth, tumor
IMD, peripancreatic tumor infiltration, and intra-abdom-
inal tumor dissemination, but not extra-abdominal me-
tastases [84]. Thus, multiple studies demonstrate the
presence of VEGF-A and VEGFRs in malignant pancreatic
ductal cells, and VEGF-VEGFR interactions appear to be
mitogenic for pancreatic cancer cells. VEGF-A, then, repre-
sents a potential single therapeutic target whose inhibi-
tion can have important and far-reaching ramifications on
both pancreatic cancer angiogenesis and tumorigenesis.
Further studies will continue to elucidate the role of
VEGF-A and its receptors, along with other pro-and anti-
angiogenic cytokines, in pancreatic cancer.
Angiogenesis inhibitors regulate pancreatic cancer growth 
and metastasis
Additional evidence supporting a crucial role for angio-
genesis in pancreatic cancer growth and metastasis comes
from the effects of anti-angiogenic compounds on tumor
growth, spread, and vascularity in vitro and in vivo. Several
studies have demonstrated decreased growth and metasta-
sis of pancreatic cancer using the fumagillin analog TNP-
470 with or without cytotoxic agents in vivo [85–87]. In
our orthotopic model of human pancreatic cancer, Hotz et
al showed that TNP-470 alone decreased tumor growth,
IMD, and metastatic spread by anti-angiogenic mecha-
nisms versus antitumor effects [87]. The endogenous anti-
angiogenic compound angiostatin, a fragment of plas-
minogen, has been shown to inhibit growth and neovas-
cularization of hepatic metastases in a hamster model of
metastatic pancreatic cancer [88].
While the aforementioned studies utilized general angio-
genesis inhibitors, other experiments have targeted specif-
ic pro-angiogenic cytokines, including VEGF-A, to inhibit
tumor growth. In our laboratory, use of a diphtheria tox-
in-VEGF fusion protein significantly decreased tumor vol-
ume, IMD, and metastasis, and increased animal survival
in vivo [89]. Interestingly, despite evidence for the pres-
ence of VEGF receptor expression in one of the cell lines
used (AsPC-1), the inhibitory effects of the fusion protein
were isolated anti-angiogenic phenomena, as the doses of
the protein showed no effect on cell growth in vitro [89].
These results underscore the findings of Itakura et al that
some pancreatic cancer cells express such low VEGFR lev-
els that they do not exhibit significant ligand-receptor in-
teractions [82]. Further examination of VEGF-A inhibition
was carried out by Bruns et al, who used an anti-VEGFR-2
antibody (DC101) with and without gemcitabine in an
orthotopic nude mouse model [90]. Treatment with
DC101 alone and gemcitabine alone both inhibited tu-
mor growth, but combination therapy inhibited growth
to a greater degree and produced demonstrable endothe-
lial cell apoptosis [90]. These results suggest that VEGF-
targeted therapies may potentiate the effects of cytotoxic
treatments in pancreatic cancer.
Therapeutic implications
Hypoxia is clearly a driving force in pancreatic cancer
growth and metastasis. The major effect of hypoxia cur-
rently appears to be that of induction of angiogenesis. Nu-
merous anti-angiogenic treatment strategies have shown
early promise for therapy of pancreatic cancer. However,
because tumor angiogenesis is regulated on multiple com-
plex levels, involves multiple pro- and anti-angiogenic cy-
tokines, and depends upon critical interactions between
tumor cells, endothelial cells, tissue resident cells, infil-
trating lymphocytes, and the extracellular matrix, single
agent approaches are unlikely to produce significant clin-
ical effects. Combination therapies targeting multiple
points along the angiogenic pathway will likely be more
effective in the treatment of pancreatic cancer. Such thera-
pies may combine VEGF-targeted molecules with matrix
metalloproteinase inhibitors, agents that incapacitate en-
zymes used by migrating endothelial and tumor cells to
degrade extracellular matrix and promote tissue invasion
[91]. While these agents showed great promise in preclin-
ical studies, initial results in clinical trials comparing
MMP-inhibition with gemcitabine have been disappoint-
ing [92]. Nevertheless, tumor angiogenesis and its endless
array of regulatory factors provides nearly limitless oppor-
tunity for the development of new therapeutic agents and/
or methods. In fact, recent studies have demonstrated fa-
vorable anti-tumor and anti-angiogenic effects using solu-
ble VEGFR products that can be delivered via viral-
encoded gene therapy [93,94]. Further intensive study of
human pancreatic adenocarcinoma pathologic specimens
may soon identify which patients stand to benefit most
from anti-angiogenic treatments. In reality, at this time re-
search exploring hypoxia and angiogenesis in pancreatic
cancer remains in its infancy. The implications of hypoxia
on cellular metabolism have not been well defined in
these tumors. As knowledge in these important areas con-
tinues to expand, new approaches to impeding tumor ne-
ovascularization will be discovered and implemented.
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